Here are the latest quarterly results of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA financial fact sheet and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
3
Sep-21* |
3
Dec-21* |
3
Mar-22* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 1,936 | 2,095 | 2,003 | 2,103 | 1,754 | 1,977 | 2,005 | 2,320 | |
Other income | Rs m | 26 | 47 | 29 | 26 | 29 | 28 | 53 | 37 | |
Turnover | Rs m | 1,962 | 2,142 | 2,032 | 2,128 | 1,783 | 2,006 | 2,059 | 2,356 | |
Expenses | Rs m | 1,650 | 1,737 | 1,695 | 1,698 | 1,598 | 1,798 | 1,859 | 1,940 | |
Gross profit | Rs m | 286 | 358 | 307 | 404 | 156 | 179 | 147 | 380 | |
Depreciation | Rs m | 46 | 46 | 51 | 58 | 48 | 43 | 35 | 44 | |
Interest | Rs m | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | |
Profit before tax | Rs m | 264 | 356 | 283 | 368 | 135 | 162 | 163 | 370 | |
Tax | Rs m | 78 | 92 | 72 | 96 | 33 | 43 | 48 | 90 | |
Profit after tax | Rs m | 186 | 263 | 211 | 273 | 102 | 119 | 114 | 280 | |
Gross profit margin | % | 14.8 | 17.1 | 15.4 | 19.2 | 8.9 | 9.1 | 7.3 | 16.4 | |
Effective tax rate | % | 29.4 | 26.0 | 25.6 | 26.0 | 24.2 | 26.4 | 29.8 | 24.4 | |
Net profit margin | % | 9.6 | 12.6 | 10.5 | 13.0 | 5.8 | 6.0 | 5.7 | 12.1 | |
Diluted EPS | Rs | 7.5 | 10.5 | 8.4 | 10.9 | 4.1 | 4.8 | 4.6 | 11.2 | |
Diluted EPS (TTM) | Rs | 27.7 | 32.5 | 30.2 | 37.3 | 34.0 | 28.2 | 24.4 | 24.6 | |
![]() |
Indian share markets witnessed a volatile trading session today as crude oil prices rebounded following last week's rout.
It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Here's why Divi's Lab's stock fell over 10% in two days.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
More Views on NewsWith India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.
Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.
Some sectors have corrected by 50%. Do they merit a look?
This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
This is how you can tell the market is going to recover.
More